Donnelley Financial Solutions (DFIN) has introduced AI Document Translation and AI Document Summaries to its Venue virtual data room, enhancing its Active Intelligence suite. These tools help deal teams quickly understand documents in over 130 languages and generate concise summaries, improving multilingual collaboration and speeding up due diligence. The features maintain strict security and governance controls, allowing sensitive information to stay protected within the platform. This innovation supports DFIN's goal to embed practical AI in high-stakes financial transactions, helping clients accelerate deals while managing complex workflows securely.
Donnelley Financial Solutions' recent AI-powered document translation and summary features provide context for technology sector trends. For readers following technology stocks, here is Pluang's market snapshot as of Sep 14, 2026 19:44 WIB: out of 150 priced US technology stocks, 67 rose and 77 fell. Notable movers include AXTI at USD 59.51 with a 1-day change of -8.12%, MRVL at USD 217.28 down 7.97%, and KLAC at USD 166.53 down 7.81%.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
